Copyright
©The Author(s) 2017.
World J Gastrointest Oncol. Apr 15, 2017; 9(4): 166-175
Published online Apr 15, 2017. doi: 10.4251/wjgo.v9.i4.166
Published online Apr 15, 2017. doi: 10.4251/wjgo.v9.i4.166
Figure 2 Prognosis of pathological stage II/III advanced gastric cancer patients who underwent curative gastrectomy followed by S1 postoperative adjuvant chemotherapy.
A: Kaplan-Meier curves for overall survival (OS) (upper panel) and relapse free survival (RFS). Five year survival is shown; B: Stage distribution of pathological stage according to the 13th Japanese Gastric Cancer Association stage in Kitasato University in comparison with the ACTS-GC trial; C: Rate of each macroscopic feature in pathological stage II/III advanced gastric cancer. High-risk macroscopic features (type IV and giant type III) are seen in 10.5% as shown in this figure.
- Citation: Yamashita K, Ema A, Hosoda K, Mieno H, Moriya H, Katada N, Watanabe M. Macroscopic appearance of Type IV and giant Type III is a high risk for a poor prognosis in pathological stage II/III advanced gastric cancer with postoperative adjuvant chemotherapy. World J Gastrointest Oncol 2017; 9(4): 166-175
- URL: https://www.wjgnet.com/1948-5204/full/v9/i4/166.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v9.i4.166